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Summary 
Major histocompatibllity complex (MHC) class II mole- 
cules bind antigenic peptides rapidly after biosynthe- 
sis in antigen-presenting cells (APCs). By contrast, the 
rate of peptide binding to purified class II molecules 
is remarkably slow. We find that purified HLA-DR mole- 
cules bind peptides rapidly in the presence but not the 
absence of HLA-DM, a recently identified heterodlmer 
required for efficient antigen processing. The same 
effect is seen with immunoprecipitated DM, sug- 
gesting that DM interacts directly with DR. Class II- 
associated Invariant chain peptides (CLIP) are selec- 
tively and rapidly released from DR during incubation 
with DM at pH 5. We conclude that DM is a cofactor that 
enhances peptide binding to DR molecules through a 
mechanism involving peptide exchange. 
Introduction 
Major histocompatibility complex (MHC) class II ab dimers 
assemble in the endoplasmic reticulum (ER) as a nonam- 
eric complex with invariant chain (Ii) in a stoichiometric 
fashion (Marks et al., 1990; Roche et al., 1991). Ii is a 
nonpolymorphic, non-MHC-encoded protein that is essen- 
tial for the proper assembly (Peterson and Miller, 1990; 
Anderson and Miller, 1992) and transport of class II dimers 
(Lamb et al., 1991; Lotteau et al., 1990; Guagliardi et al., 
1990; Neefjes et al., 1990; Bakke and Dobberstein, 1990). 
In addition, the invariant chain may block the association 
of peptides with class II in the ER (Teyton et al., 1990), 
preventing the binding sites from being saturated with en- 
dogenous peptides. Binding of invariant chain and peptide 
to class II is mutually exclusive (Roche et al., 1992; Teyton 
et al., 1990; Rocheand Cresswell, 1990a, 1991; Newcomb 
and Cresswell, 1993). The class II-ii complex is targeted 
to the endosomal pathway, where the Ii protein is de- 
graded and class II is released. Recent reports have impii- 
cated a specialized endocytic compartment, MIIC, where 
empty class II may encounter and load peptides derived 
from exogenous antigen (Qiu et al., 1994; Amigorena et 
al., 1994; Tulp et al., 1994; West et al., 1994). 
CLIP is the region of invariant chain (residues 81-105) 
that is responsible for both association with class II and 
inhibition of peptide binding (Romagnoli and Germain, 
1994; Bijlmakers et al., 1994). The CLIP peptide has been 
eluted from both mouse and human class Ii molecules 
(Hunt et al., 1992; Rudensky et al., 1991; Riberdy et al., 
1992; Chicz et al., 1992) and is probably a product of Ii 
proteolysis in the endocytic pathway. Class II-CLIP com- 
plexes can be generated in vitro by digestion of DR aj3li 
with the endosomal proteases cathepsins 6 and D (Awa 
and Cresswell, 1994). 
The rate of association and dissociation of the peptide- 
class II complex are unusual compared with other recep- 
tor-iigand interactions. In experiments using purified class 
II, the rate of association is very slow, requiring 24-48 hr to 
reach saturation (Buus et al., 1986; Roche and Cresswell, 
1990b). Once formed, the complex is stable with an even 
slower dissociation rate (Buus et al., 1986). The dissocia- 
tion kinetics are consistent with the physiological role of 
class II molecules, which present a variety of peptides 
by displaying them on the antigen-presenting ceil (APC) 
surface long enough to be scrutinized byT cells. However, 
the observed association rate using purified class II does 
not explain the rapid physiological peptide loading that 
occurs within the APC in vivo. Many laboratories report 
that antigen-derived peptide associates with class II in 
cells after only 20-60 min (Roosneck et al., 1988; David- 
son et al., 1991; Marsh et al., 1992; Harding and Geuze, 
1992). In addition, a large fraction of class II molecules 
become stable as dimers in SDS (which is indicative of 
stable association with peptide; Germain and Hendrix, 
1991) within a few hoursof biosynthesis (Amigorena et al., 
1994; Castellino and Germain, 1995). These observations 
imply the presence of one or more cofactors expressed in 
APC that are responsible for the enhanced rate of peptide 
binding to class II. 
A number of antigen-processing mutant ceil lines have 
been described that can present peptide but not protein 
antigens (Mellins et al., 1990, 1991; Riberdy and Cress- 
well, 1992; Ceman et al., 1992). Although these cells express 
wild-type ii and class II molecules, the class II isolated 
from these cells exhibit certain biochemical differences 
when compared with class II in normal cells. First, although 
the aj3 dimers assemble normally, they lack certain confor- 
mationally specific antibody epitopes (Riberdy and Cress- 
well, 1992). Second, the class II molecules do not acquire 
stability in SDS (Riberdy and Cresswell, 1992). Finally, 
class II heterodimers from mutant cells are predominantly 
associated with the CLIP peptide (Riberdy et al., 1992). 
Studies with these mutant cell lines have mapped the 
defect to the MHC-encoded nonclassical class II protein 
termed DM (Morriset al., 1994; Fling et al., 1994). Expres- 
sion of DM in the mutant ceils restores conformational 
epitopes and SDS stability to class II, and association with 
CLIP is reduced (Denzin et al., 1994). DM localizes to the 
class II-containing endocytic vesicles but is not found at 
the cell surface (Karlsson et al., 1994; Denzin et al., 1994; 
Sanderson et al., 1994). A recent study found that DM, 
class II, and Ii are the minimal factors required for forma- 
tion of mature SDS-stable class II in non-APCs (Karlsson 
et al., 1994). 
Several mechanisms have been suggested for DM func- 
tion. It may act as a molecular chaperone, to target either 
class ii or antigenic peptides to an endocytic compartment 
where peptide loading occurs. Alternatively, DM may be 
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a CLIP “sink”, which absorbs invariant chain peptides cre- 
ated during Ii degradation, preventing class II from being 
saturated with CLIP instead of antigenic peptides. Finally, 
DM may be a catalyst for the peptide loading step, either 
helping to release CLIP from class II or directly enhancing 
the binding of peptides toclass II molecules. Todistinguish 
between these possibilities, we reconstituted purified ma- 
ture DRl into DM-containing membranes and measured 
the peptide loading of these class II molecules. We found 
that DM directly enhances peptide loading of class II by 
facilitating CLIP release. These results identify DM as the 
factor responsible for rapid peptide loading within APC 
and explain the phenotype of the mutant APCs. 
Results 
MHC-Linked Genes Control Peptide Loading 
by DRl Molecules 
Purified class II molecules bind peptide antigens ex- 
tremely slowly, requiring 24-48 hr to reach saturation 
(Buus et al., 1986; Roche and Cresswell, 1990b; Jensen, 
1991). However, class II molecules load with peptides 
within a few hours after synthesis in vivo (Davidson et al., 
1991; Amigorena et al., 1994; Castellino and Germain, 
1995; Roosneck et al., 1988), raising the possibility that 
cofactors may facilitate peptide loading under physiologi- 
cal conditions (Jensen, 1991). This possibility was sup- 
ported by preliminary studies demonstrating that the rate 
of peptide binding is enhanced after reconstitution of puri- 
fied class II proteins into liposomes containing membrane 
components from B lymphoblastoid cells (data not shown). 
Membranes from wild-type Tl and mutant T2 lymph- 
oblastoid cells were reconstituted into liposomes with puri- 
fied DRl by detergent dialysis to determine whether a 
putative cofactor(s) is encoded in the MHC. T2 cells have 
a large homozygous deletion in the MHC, which includes 
all class II structural genes and the genes that encode DM 
(DeMarset al., 1984; Erlich et al., 1986; Salteret al., 1985). 
Each liposome preparation contained similar amounts of 
DRl as determined by immunoassay (data not shown). 
Biotinylated peptides were incubated with the liposomes 
at acidic pH, and biotin-peptide/class II complexes were 
measured. DRl bound significantly more peptide during 
a 3 hr incubation when reconstituted into Tl membranes 
compared with T2 membranes. This enhanced binding 
was observed using three peptides with binding specifici- 
ties for DRl, but not with a control peptide having a differ- 
ent binding motif (Figure 1). Tl expresses endogenous 
DRi’(Salter et al., 1985), which did not bind to the peptides 
used in this experiment. These results indicate that acom- 
ponent(s) in Tl but not T2 membranes enhances peptide 
binding to DRl molecules. 
Enhanced Peptide Binding in the Presence 
of HLA-DM 
Tl cells express a number of MHC class II-encoded pro- 
teins that are not present in T2 cells, including DM. To 
identify DM specifically as the cofactor involved in efficient 
peptide loading, we transfected L cells with both DMA and 
DMB genes. Expression of DMa and DMp proteins was 
confirmed by Western blot analysis using specific rabbit 
antisera (Figure 2A). Liposomes of D&expressing L cell 
membranes were reconstituted with purified DRl. Again, 
DRl showed greater ability to bind peptide during a 3 hr 
incubation in the presence of DM compared with DRl in 
control liposomes (Figure 28). The enhanced binding in 
the presence of DM is most striking during short incuba- 
tions, as shown in Figure 2C. After 32 hr, the quantity of 
DRl-peptide complexes in L cell liposomes approached 
that in LDM liposomes. Peptide loading was optimal at 
low pH (Figure 2D), consistent with the hydrogen ion con- 
centration present in endosomal compartments. These re- 
sults point to DM as a cofactor that may catalyze peptide 
binding to available class II molecules. 
A Direct Effect of DY on Peptide Binding 
by Detergent-Solublized DR1 
A number of experiments demonstrated that the observed 
activity depends on the concentration of DM. Liposomes 
were generated by mixing different proportions of solubi- 
lized membranes from L cells and LDM transfectants be- 
fore addition of DRl and dialysis. The enhancement of 
peptide binding was proportional to the relative quantity 
of LDM membranes (Figure 3A). In addition, the activity 
of membranes from various sublines of LDM transfectants 
correlated with the level of DM expression measured in 
Western blots (Figure 38). 
We found that membrane reconstitution was not re- 
quired for DM to function. Detergent-solubilized LDM 
membranes but not L cell membranes enhanced peptide 
binding by purified DRl (Figure 3C). The above results 
did not exclude the possibility that DM may act indirectly 
by influencing the concentration or activity of another fac- 
torthat actsdirectlyon DRl. Toaddress this possibility, we 
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Figure 1. Peptide Binding by DRl in Reconstituted Tl and T2 Mem- 
branes 
Liposomes containing 50 ug TI or T2 membrane protein and 20 pmol 
DRl (if indicated) were incubated with 1 uM biotinylated peptide for 
3 hr at 37%. After solubilization with NP40 buffer, biotin-peptide/ 
class II complexes were detected by europium fluorescence assay as 
described in Experimental Procedures. 
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Figure 2. Effect of DM on Peptide Binding to DRl in L Cell Transfectant Membrane Liposomes 
(A) Western blot analysis of DM protein expression in cell lines. Membranes (15 ug) from Tl , T2, L cells (L), and L cell sublines transfected with 
DMA and DMB genes (LDM) were resolved on SDSPAGE and probed with antisera to DMa or DMf3. The approximate apparent molecular masses 
of DMa and DM5 were 34 and 30 kDa, respectively. 
(B) Enhanced peptide binding to DRl reconstituted into liposomes containing LDM compared with L cell membranes. Liposomes (50 sg protein) 
from LDM and untransfected L cells containing 20 pmol DRI were incubated with biitinylated peptides (1 pM) for 3 hr at 37% (pli 5) in the 
presence of protease inhibitors. Peptide binding was measured as described in Experimental Procedures. 
(C) Kinetics of peptide binding in the presence of DM. DRi-containing liposomes were incubated with 1 uM biotin-MAT (17-31) at 37% (pH 5) 
for the indicated length of time and bound peptide was measured. 
(D) Effect of pH on MAT (17-31) binding to DRI in the presence of DM. Liposomes containing 20 pmol DRI were incubated with 1 uM biotin- 
MAT (17-31) in 0.1 M citrate/phosphate buffer at the indicated pH for 3 hr at 37% and bound peptide was measured. 
studied the effectof immunoprecipitated DM moleculeson 
peptide binding. DM was captured from detergent- 
solubilized Tl membranes with antiserum specific for the 
cytoplasmic domain of DMp. Captured DM directly en- 
hanced peptide binding by purified DRl (Figure 3D). No 
enhancement was seen in control groups with preimmune 
serum or T2 cell membranes. The same results were ob- 
tained with DM captured from solubilized LDM mem- 
branes (Figure 3E). 
The population of class II that is available to bind peptide 
could be empty or bound with easily removed peptides, 
such as CLIP. To determine directly whether DM can in- 
duce the dissociation of peptide, preloaded biotin-pep- 
tide/DRl complexes were incubated with LDM mem- 
branes. DM induced the dissociation of CLIP but not the 
high affinity antigenic peptides HA (306-316) (Figure 4A) 
or MAT (17-31) (data not shown). Addition of unlabeled 
MAT (17-31) did not further enhance DM-induced CLIP 
dissociation. 
DM Induces the Release of Class II-Associated A role for DM in facilitating the replacement of CLIP with 
Invariant Chain Peptldes antigenic peptide was further supported by the results of 
Similar amounts of peptide-class II complexes are gener- experiments with DR3 isolated from DM-deficient cells. A 
ated after long incubations whether DM is present or not. major fraction of DR3 molecules isolated from T2 transfec- 
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Figure 3. Direct Effect of DM on Peptide Binding by DRI 
(A) Bolubilized L and LDM membranes were mixed in various relative amounts, keeping the final membrane concentration in each sample equal. 
DRI (0.4 pM) was added before detergent dialysis. The liposomes (containing 20 pmol DRl) were incubated with 1 pM biotin-MAT (17-31) for 
3 hr and biotin-peptide/DRl complexes were measured as described in Experimental Procedures. 
(B) LDM sublines expressing different amounts of DMa show corresponding degrees of enhanced peptide binding. Membranes from Tl, T2, L, 
and several LDM sublines were reconstituted into liposomes with DRI as described above. Each liposome preparation contained exactly the same 
amount of membrane protein as measured by BCA assay. Borne liposomes were incubated with 1 pM biiin-MAT (17-31) for 3 hr and biitin- 
peptide/class II complexes were quantifisd with the europium assay. The remaining liposomes were solubilixad in SDS sample buffer and run in 
reducing SDS-PACE. Western blots were used to measure relative amounts of DMs and DR as described in Experimental Procedures. We also 
found that the presence of DM5 as determined by Western analysis is absolutely required for function (data not shown). 
(C) Detergent-solubilized membranes containing DM enhance peptide binding to purified DRl. L and LDM membranes were solubilized in 0.5% 
NP-40 and serial dilutions were incubated with 10 pmol DRl, 1 pM biotin-MAT (17-31). and protease inhibitors at pli 5 for 3 hr at 37% followed 
by measurement of bound peptide. 
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Figure 4. DM Induces the Dissociation of CLIP from DR Molecules 
(A) Dissociation of synthetic CLIP from DRI. Preformed DRl complexes containing biotin-CLIP or biotin-HA (309-319) (2 pmol) were incubated 
with 50 ug solubilized membranes in the presence or absence of 5 uhf unlabeled MAT (17-31) for 5 hr at 37OC and remaining biotin-peptide/ 
DRl complexes were measured. 
(8) Formation of SDS-stable DR3 dimers in the presence of DM. DR3 (2 pmol) was incubated with 25 ug solubilized L or LDM membranes for 
5 hr at pH 5. Some samples contained 5 pM HSP(3-13). After pH neutralization and addition of 2% SDS, unheated samples were analyzed by 
SDS-PAGE and Western blotting with DR-specific antisera. Relative quantities of unstable and stable dimers were determined by densitometry. 
Percent of each sample in the stable versus unstable form is indicated in parentheses. 
(C) Enhanced peptide binding to DR3 in the presence of DM. DR3 (0.5 pmol), isolated from transfected mutant T2 cells (Riberdy et al., 1992) 
was incubated for 5 hr with 1 uM biotin-HSP(3-13) in the presence of 50 ug solubilized L or LDM membranes. 
tants is associated with CLIP and these complexes are tide. It is likely that peptides or unfolded proteins (Jensen, 
unstable in SDS (Riberdy et al., 1992). We isolated DR3 1993) contributed by the solubilized membranes bind to 
from T2 transfectants and found that approximately 50% DR3 to form stable dimers in the presence of DM. The 
was unstable in SDS. The fraction of unstable molecules binding of the peptide antigen, biotin-HSP(3-13) to DR3 
was greatly reduced after a 5 hr incubation in the presence was markedly enhanced in the presence of DM (Figure 
of DM (Figure 48). The shift from unstable to stable dimers 4C). Thus, our observations support the conclusion that 
in the presence of DM is not dependent on additional pep- DM facilitates the replacement of physiologically loaded 
(D) Activity of DM captured from Tl membranes. Solubilized membranes from Tl or T2 cells were incubated with protein A-Sepharose that had 
been preloaded with preimmune serum (control) or antiserum specific for the cytoplasmic domain of DMf3. After washing, the Sepharose was 
incubated for 3 hr with 2 pmol purified DRl and 1 pM biotin-MAT (17-31) at 37OC and bound peptide was measured. 
(E) Activity of DM captured from LDM membranes. DM was captured as in (D) and incubated for 3 hr with 20 pmol DRl and 1 uM biotin-MAT 
(17-31). 
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CLIP by antigenic peptide. DM may also enhance peptide 
binding to mature DRl by inducing the release of other 
peptides that share physical characteristics with CLIP. 
Discussion 
This study demonstrates that DM enhances peptide bind- 
ing by DR molecules through a mechanism involving the 
release of previously bound peptides. This is primarily a 
kinetic effect and only a subpopulation of molecules is 
susceptible to peptide exchange. Our results suggest that 
DM acts through a direct interaction with class II molecules 
because immunoprecipitated DM enhances peptide bind- 
ing to purified DRl . The presence of DM is clearly required 
for this activity, because the degree of enhancement is 
proportional to the concentration of DM, and no enhance- 
ment is seen with control immunoprecipitates from DM- 
negative cells or with preimmune serum. We cannot rule 
out the presence of another factor, coprecipitating with 
DM. No proteins have yet been identified that coprecipitate 
with DMalDM8 isolated from metabolically labeled cells 
(Denzin et al., 1994; Sanderson et al., 1994). However, the 
data presented here do not formally exclude the possibility 
that a coprecipitating factor may be involved. 
Our results demonstrate that CLIP but not the high affin- 
ity peptides, HA (306318) and MAT (17-31) are rapidly 
released from DRl molecules in the presence of DM. CLIP 
dissociation is nearly complete after a 5 hr incubation with 
DM. The weight of evidence suggests that CLIP is associ- 
ated with class II molecules through the peptide-binding 
site (Romagnoli and Germain, 1994; Bijlmakers et al., 
1994; Malcherek et al., 1995; Sette et al., 1995; Sinigaglia 
and Hammer, 1995). The rapid peptide loading of DR3 
molecules isolated from T2 transfectants can readily be 
accounted for by a mechanism involving the release of 
CLIP to generate empty peptide binding sites. Supporting 
this conclusion, we observed that 65%-800/o of SDS- 
unstable DR3 molecules are converted to stable dimers 
during a 5 hr incubation with DM. Since CLIP-DR com- 
plexes(Mellinset al., 1990; Riberdyet al., 1992)andempty 
DR molecules (Stern and Wiley, 1992) are unstable in 
SDS, whereas many other peptide-class II complexes are 
stable (Germain and Hendrix, 1991) this conversion to 
stable molecules reflects exchange of CLIP for other poly- 
peptides. The release of CLIP may also account for the 
effect of DM on peptide binding to DRl molecules isolated 
from DM-expressing LG2 B lymphoblastoid cells. Despite 
the expression of DM, a significant fraction of mature DRl 
molecules in these cells are also associated with CLIP 
(Urban et al., 1994). 
We speculate that DM binds to class II molecules and 
either induces a conformational change or shifts an equi- 
librium towards a conformation associated with rapid re- 
lease of CLIP. It is possible that DM interacts only with a 
subset of class II molecules that assume a specific confor- 
mation, which is dependent on the nature of bound pep- 
tide. CLIP-bearing DR molecules have a different confor- 
mation from DR molecules bearing most other peptides 
acquired under physiological conditions. Unlikeother pep- 
tide complexes, CLIP-DR complexes are unstable in SDS 
(Mellins et al., 1990; Riberdy et al., 1992) and have re- 
duced affinity for certain monoclonal antibodies (Mellins 
et al., 1990, 1991; Morris et al., 1994; Fling et al., 1994), 
reflecting the absence of specific conformational epitopes. 
Alternatively, DM may interact with all class II molecules, 
inducing a conformation that favors the release of selected 
peptides that have nonoptimal anchor residues. CLIP dif- 
fers from most peptides in that it is able to bind to many 
different class II alleles. This promiscuous binding speci- 
ficity is possible because the peptide has amino acid side 
chains at key anchor positions that can be accommodated 
by pockets formed by polymorphic residues in different 
class II alleles (Malcherek et al., 1995; Sette et al., 1995; 
Sinigaglia and Hammer, 1995). The lack of allele-specific 
anchors in the peptide may compromise stability of 
binding. 
Several reports demonstrate that CLIP-DR complexes 
are particularly sensitive to low pH (Riberdy et al., 1992; 
Urban et al., 1994; Awa and Cresswell, 1994). CLIP, un- 
like most peptides, is selectively released from DRl mole- 
cules during a 24 hr incubation at pH 4 (Urban et al., 1994). 
This sensitivity to acid-induced dissociation may reflect 
nonoptimal binding interactions with DR. Peptide binding 
by purified (Jensen, 1991; Sadegh-Nasseri and Germain, 
1991; Reay et al., 1992) and cell surface (Jensen, 1990; 
Sherman et al., 1994) class II molecules is generally opti- 
mal at low pH. Studies with conformation-sensitive probes 
indicate that class II molecules undergo a definite struc- 
tural transition at mildly acidic pH, approximating the pH 
found in acidic endosomal vesicles (H. A. Runnels, J. C. 
Moore, and P. E. J., submitted). The enhanced peptide 
binding observed at low pH may, at least in part, be a 
result of the release of CLIP or other peptides from a sub- 
population of class II molecules. The marked pH depen- 
dence of peptide binding is preserved when binding is 
facilitated by DM (Figure 2D). It is possible that the interac- 
tion of DM with DR may be influenced by pH-induced 
changes in the structure of DM or the charge of critical 
contact residues in DM or DR. Alternatively, the low pH 
conformer of DR may be a preferred substrate for DM. The 
latter possibility seems more likely given the documented 
effect of pH on the structure and function of purified class 
II molecules. 
The ability to catalyze the binding of antigenic peptides 
to CLIP-bearing class II molecules is sufficient to explain 
the phenotype of mutant cells without postulating other 
roles previously considered for DM. One need not propose 
a chaperone function for DM, since a trafficking require- 
ment for class II or antigen has been eliminated in our 
experimental system. Although acidic pH has been shown 
to enhance the dissociation of CLIP from DR molecules, 
the large fraction of molecules associated with CLIP in 
DM-deficient cells (Riberdy et al., 1992) indicates that the 
pH encountered in endosomal compartments is not low 
enough to release CLIP from more than a small fraction 
of the molecules during the transport of newly synthesized 
DR to the cell surface. As previously demonstrated, occu- 
pancy with CLIP as opposed to other peptides accounts 
for the large fraction of SDS-unstable molecules in mutant 
cells (Mellins et al., 1990; Riberdy et al., 1992) and CLIP 
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blocks the binding of antigenic peptides (Riberdy et al., 
1992; Romagnoli and Germain, 1994; Bijlmakers et al., 
1994), accounting for the observed deficiency in antigen 
processing function (Mellins et al., 1990; Riberdy and 
Cresswell, 1992; Ceman et al., 1992; Morris et al., 1994). 
Our results help to resolve an apparent contradiction in 
the kinetics of peptide-class II formation. Purified class II 
binds peptide extremely slowly, requiring 24-48 hr to 
reach saturation (Buus et al., 1988; Roche and Cresswell, 
1990b). By contrast, peptide loading occurs rapidly under 
physiological conditions in viable APC (Roosneck et al., 
1988; Ceppellini et al., 1989; Davidson et al., 1991; Ami- 
gorena et al., 1994; Castellino and Germain, 1995). Al- 
though the peptide association rate can be strikingly en- 
hanced at the low pH characteristic of endosomal 
compartments (Jensen, 1991; Reay et al., 1992) this fac- 
tor alone cannot account for the enhanced kinetic seen in 
vivo. In earlier studies using T cell activation as an indirect 
measure of peptide binding to cell surface class II mole- 
cules, we found that binding approached maximal levels 
within 2-4 hr, raising the possibility that a cofactor present 
in the APC membrane may facilitate peptide binding to 
class II molecules (Jensen, 1990, 1991). However, more 
recent biochemical peptide binding experiments demon- 
strate that this cofactor is present in intracellular but not 
cell surface membranes (data not shown). The results of 
the present study support the conclusion that DM is the 
cofactor responsible for efficient peptide loading in APC. 
In mutant cells lacking functional DM, most class II mole- 
cules reach the cell surface without binding antigenic pep- 
tide because of the slow intrinsic rate of CLIP dissociation 
and peptide exchange. 
Experimental Procedures 
call Culture 
Tl and T2 human (.174 x CEM. Tl and ,174 x CEM. T2) hybrids 
(Salter et al., 1965) were cultured in DMEM containing 10% fetal calf 
serum, 2 mM L-glutamine, 2 mM sodium pyruvate, and the antibiotics 
penicillin-streptomycin and gentamicin. L cells (DAP-3, t/r subclone 
of murine L cells) were cultured in RPM1 containing the same additives 
and 50 mM 2-ME (RIO). Cells were maintained at 37OC in 7% CO*. 
T2-DR3 cells (Riberdy et al., 1992) were a gift of P. Cresswell (Yale 
University, New Haven, Connecticut). Media and additives were pur- 
chased from GIBCO BRL (Grand Island, New York). 
Peptides 
Peptides were synthesized as previously described (Jensen, 1991). 
MAT (17-31). sequence: SGPLKAEIAQRLEDV; HIV gp41(577-595) 
sequence: GIKQLQARILAVERYLKDQ; NP7TPQ(535-551), sequence: 
LDPLIRGLLARPAKLQV; Rabies NS(lOl-120) sequence: GVQIVRQ- 
IRSGERFLKIWSQ; HSP(3-13) sequence:KTIAYDEEARR; and CLIP, 
sequence:LPKPPKPVSKMRMATPLLMGALPM. Peptides were la- 
beled with biotin at the o amino group by reaction with biotin amidoca- 
proate N-hydroxysuccinimide (Jensen, 1991). 
Constructlon and Expression of HLA-DMA and HLA-DMB 
cDNA Expression Vectors 
Total RNA was prepared from LG2 lymphoblastoid cells using TRlzol 
reagent (GIBCO BRL). cDNA was synthesized by reverse tran- 
scriptase-polymerase chain reaction (RT-PCR) using GIBCO BRL 
reagent kit. Full-length HLA-DMA and HLA-DMB were amplified from 
cDNA by PCR using Taq polymerase (Boehringer-Mannheim Corpora- 
tion, Indianapolis, Indiana) and standard PCR conditions. The primers 
used to amplify cDNA clones were designed with a restriction site for 
cloning: Spel-DMA/F (plus strand, 5’ end of DMA) 5’-CTGTGTGACT- 
AGTAGGTATGGGT-3’; Notl-DMAIR (minus strand, 3’ end of DMA) 
5’-CAGCGCGGCCGCTGGCATCAAACTCTGGTCTGGA-3’; Kpnl- 
DMB/F (plus strand, 5’ end of DMB) 5%AGTGGTACCATCTTTACA- 
GAGCAGAGCATGATC-3’; Notl-DMBIR (minus strand, d’end of DMB) 
5’-CAGCGCGGCCGCTCCTTCTCACTTGGAGTGGAAGTTG-3’. Am- 
plified products of DMA (643 bp) were subcloned into eukaryotic ex- 
pression vector pRC/RSV (neomycin+) and DMB (657 bp) into pCEP4 
(hygromycin B+) (both from lnvitrogen Corporation). DAP-3 cells (2.5 
x Iq (a f/r subclone of murine L cells) were transfected with 2.5 ug 
each DMA and DMB constructs resuspended with 20 ug lipofectin 
reagent (GIBCO BRL). After 24 hr, double selection was initiated with 
500 pg/ml each G416 (GIBCO BRL) and hygromycin B (Sigma). Stable 
DM transfectants were cloned by limiting dilution and selected for high 
expression of both DMa and DM6 chains (analyzed by Western blots) 
and maximal effect on DRl peptide binding. 
Antlbodlea 
L243 anti-DR a6 (Lampson and Levy, 1960) and LB3.1 (Stern and 
Wiley, 1992) were purified from hybridoma culture supernatant using 
protein A-Sepharose beads (Pharmacia). 
Rabbi antisera to DMa and DM6 were prepared as follows: Antise- 
rum to the soluble portion of DMa (sDMA) was made by immunizing 
a rabbit with a recombinant sDMa-GST (glutathione-s-ribosyl trans- 
ferase) fusion protein. A 701 bp fragment of DMA (from the 5’ end of 
DMA to the transmembrane region) was amplified from DMA cDNA 
construct using as forward primer: BamHI, 5’-CCTAGGATCCGTGTG- 
GCAAGAAGGTATGGGT-3’ and reverse primer EcoRI, 5”CGCGGA- 
ATTCTTACTCCAGCAGATCTGAGGGCAG-3’, and subcloned into 
pGEX-2T (Pharmacia) for expression in Escherichia Coli BL2l(D2). 
sDMa-GST fusion protein was purified from bacterial extracts and 
used as immunogen. Rabbit sera were extensively absorbed with GST 
purified from extracts of bacterial cultures transformed with pGEX-PT 
alone, and used at l/l000 dilution in Western blot analyses. Rabbit 
anti-DM6 antiserum was made by immunizing with the DM6 C-terminal 
synthetic peptide, GHSSMPLPGSNYSEGWHIS, conjugated to key- 
hole limpet hemocyanin. Affinity-purified antibodies were eluted from 
Sepharose beads conjugated with the same peptide. 
Reconetltutlon of DR in Membranes and Llposomes 
DRl was purified from the Epstein-Barr virus-transformed homozy- 
gous LG2 B cell line (DRBl’OlOl) and DR3 was purified from T2 
transfectants(Riberdyetal., 1992). usingamonoclonal antibody LB3.1 
(Stern and Wiley, 1992) immunoaffinity column as previously de- 
scribed (Jensen, 1991). Purified DR was stored in buffer containing 1% 
Noctylglucoside at 4OC and analyzed by SDS-PAGE and Coomassie 
bluestaining. Protein was measured by bicinchoninic acid (BCA) assay 
(Pierce, Rockford, Illinois). 
Membranes were prepared from Tl and T2 cells or trypsinized L 
cells by hypotonic lysis (10 mM Tris [pH 6.01) in the presence of prote- 
ase inhibitors: 5 mM phenanthroline, 4 mM PMSF, 15 mM pepstatin, 
566 mM TPCK, 1 mM benzamidine, 1 mM iodoacetamide, 6 mM NEM, 
10 mM leupeptin, 270 mM TLCK, and 10 mM EDTA as previously 
described (all available from Sigma Chemical Company, St. Louis, 
Missouri). Suspensions were cleared of debris and nuclei by centrifu- 
gation at 3500 x g for IO min at 4OC, and membranes pelleted from 
supernatants by centrifugation at 22,000 x g for 30 min at 4OC. Mem- 
branes were solubilized in 0.5% s-octyi glycopyranoside in phosphate- 
buffered saline (PBS) with protease inhibitors in the presence or ab- 
sence of 0.4 uM purified DRl. The solubilized membranes were 
extensively dialyzed against PBS to form liposomes. They were used 
directly in binding assays. Protein content was measured by BCA 
assay. 
Peptida Bindlng Assay 
Peptide-class II binding assay has been previously described (Sher- 
man et al., 1994). In brief, assays were performed in triplicate and 
reproduced at least three times. Each sample was comprised of lipo- 
somes containing 50 ug membrane protein and 20 pmol DRl (if indi- 
cated). The liposomes were incubated with 1 mM biotin-peptide in 
0.1 M citrate/phosphate buffer (pH 5) and protease inhibitors for 3 hr 
at 37OC. An equal volume of solubilization buffer (1% NP-40, 0.1% 
Tween 20. 0.1 M NaCI, 400 mM Tris [pH 7.51, 1 mglml bovine serum 
albumin) was added to each sample before incubation on ice for 30 
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min. The samples were added to assay plates coated with the anti-DR 
antibody L-243. After washing, excess europium-avidin was added 
and fluorescence was read at 612 nm as described (Sherman et al., 
1994). Results, expressed as fluorescence counts per second (cps x 
lO-3), are comparable within each assay but not between assays. 
lmmunoblot Analysis 
Western blots were performed as described previously (Sherman et 
al., 1994) using donkey anti-rabbit horseradish peroxidase and chemi- 
luminescent substrate (Amersham). Quantification of bands in immu- 
noblots was accomplished by optical densitometry using a high resolu- 
tion CCD camera and the Macintosh-based software, Image (W. 
Rasband). Using Image, optical density values were determined for 
each band. The black level was adjusted to ensure linearity of the 
densitometry analysis. 
Peptlde Blnding Assay In the Presence of Captured DY 
Membranes were solubilized in PBS containing 0.5% NP-40 and prote- 
ase inhibitors. Solubilized membranes were added to tubes containing 
purified DRl and peptide in buffer with a final concentration of 0.5% 
NP-40 and 0.1 M citrate/phosphate (pH 5). Protein A-Sepharose (25 
@ample) was incubated with 25 pl serum for 1 hr at 4OC and washed 
twice with PBS followed by incubation with 100 pg membrane protein 
for 1 hr at 4OC. After further washes, the Sepharose was incubated 
with purified DRI and peptide in 50 pl volumescontaining 0.2% NP-40, 
0.1 M citrate/phosphate buffer (pH 5) and protease inhibitors. 
Releass of CLIP from Preformed DRl-CLIP Complexes 
Preformed biotin-peptide/DRl complexes were made by incubating 
6.6 uM DRl with 60 uM biotin-CLIP (LPKPPKPVSKMRMATPLLM- 
GALPM) or biotin-HA (306-318) (Stern and Wiley, 1992) for 72 hr 
at 37OC. Unbound peptide was removed by extensive dialysis. The 
complexes were used in peptide binding assays with L or LDM mem- 
branes as described above. 
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